Zaccaria A, Martinelli G, Testoni N, Zuffa E, Farabegoli P, Russo D, Guerrasio A, Tura S
Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia Lorenzo e Ariosto Seràgnoli, Università degli Studi, Bologna, Italia.
Leuk Lymphoma. 1995 Jan;16(3-4):231-6. doi: 10.3109/10428199509049762.
The prognostic value of the site of DNA rearrangement within the M-BCR on chromosome 22 or of the type of transcript has been debated in the last years. The majority of the studies do not support the hypothesis of a predictive value of such molecular parameters. Results coming from a multicentric, prospective trial, based on alpha-IFN therapy, seem to indicate a better karyotypic response in 3' rearranged patients. The possibility of evoking a cytotoxic immune response directed towards peptides originating from each of the different BCR/ABL junctions constitute an important challenge for the future.
过去几年里，22号染色体上M-BCR内DNA重排位点或转录本类型的预后价值一直存在争议。大多数研究不支持此类分子参数具有预测价值的假说。一项基于α-干扰素治疗的多中心前瞻性试验结果似乎表明，3'端重排患者的核型反应更好。引发针对源自每个不同BCR/ABL连接点的肽的细胞毒性免疫反应的可能性，是未来的一项重要挑战。
